135 related articles for article (PubMed ID: 38875031)
41. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease.
Cohen S; van Dyck CH; Gee M; Doherty T; Kanekiyo M; Dhadda S; Li D; Hersch S; Irizarry M; Kramer LD
J Prev Alzheimers Dis; 2023; 10(4):771-777. PubMed ID: 37874099
[TBL] [Abstract][Full Text] [Related]
42. Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression.
van de Beek M; van Steenoven I; van der Zande JJ; Barkhof F; Teunissen CE; van der Flier WM; Lemstra AW
Mov Disord; 2020 May; 35(5):859-867. PubMed ID: 32048343
[TBL] [Abstract][Full Text] [Related]
43. Factors associated with quality of life in patients with Alzheimer's disease.
Barbe C; Jolly D; Morrone I; Wolak-Thierry A; Dramé M; Novella JL; Mahmoudi R
BMC Geriatr; 2018 Jul; 18(1):159. PubMed ID: 29986669
[TBL] [Abstract][Full Text] [Related]
44. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
45. Cognitive and Functional Decline in Patients With Mild Alzheimer Dementia With or Without Comorbid Diabetes.
Ascher-Svanum H; Chen YF; Hake A; Kahle-Wrobleski K; Schuster D; Kendall D; Heine RJ
Clin Ther; 2015 Jun; 37(6):1195-205. PubMed ID: 25676448
[TBL] [Abstract][Full Text] [Related]
46. Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment.
Pyun JM; Ryoo N; Park YH; Kim S
Alzheimers Res Ther; 2021 Jan; 13(1):10. PubMed ID: 33402198
[TBL] [Abstract][Full Text] [Related]
47. A Real-World Evidence Analysis of Associations Among Costs, Quality of Life, and Disease-Severity Indicators of Alzheimer's Disease in Thailand.
Kongpakwattana K; Dejthevaporn C; Krairit O; Dilokthornsakul P; Mohan D; Chaiyakunapruk N
Value Health; 2019 Oct; 22(10):1137-1145. PubMed ID: 31563256
[TBL] [Abstract][Full Text] [Related]
48. Accelerated hypometabolism with disease progression associated with faster cognitive decline among amyloid positive patients.
Yang Z; Cummings JL; Kinney JW; Cordes D;
Front Neurosci; 2023; 17():1151820. PubMed ID: 37123373
[TBL] [Abstract][Full Text] [Related]
49. Cross sectional observational study on the societal costs of Alzheimer's disease.
Mesterton J; Wimo A; By A; Langworth S; Winblad B; Jönsson L
Curr Alzheimer Res; 2010 Jun; 7(4):358-67. PubMed ID: 19939223
[TBL] [Abstract][Full Text] [Related]
50. Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis.
Aye S; Bouteloup V; Tate A; Wimo A; Handels R; Jean D; Winblad B; Jönsson L
Alzheimers Res Ther; 2023 Nov; 15(1):200. PubMed ID: 37968734
[TBL] [Abstract][Full Text] [Related]
51. Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours.
Haro JM; Kahle-Wrobleski K; Bruno G; Belger M; Dell'Agnello G; Dodel R; Jones RW; Reed CC; Vellas B; Wimo A; Argimon JM
J Nutr Health Aging; 2014 Jul; 18(7):677-84. PubMed ID: 25226106
[TBL] [Abstract][Full Text] [Related]
52. Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.
Herring WL; Gould IG; Fillit H; Lindgren P; Forrestal F; Thompson R; Pemberton-Ross P
Neurol Ther; 2021 Dec; 10(2):919-940. PubMed ID: 34426940
[TBL] [Abstract][Full Text] [Related]
53. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MGEKN; Tabet N
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
[TBL] [Abstract][Full Text] [Related]
54. Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden.
Sheikh F; Ismail Z; Mortby ME; Barber P; Cieslak A; Fischer K; Granger R; Hogan DB; Mackie A; Maxwell CJ; Menon B; Mueller P; Patry D; Pearson D; Quickfall J; Sajobi T; Tse E; Wang M; Smith EE;
Int Psychogeriatr; 2018 Feb; 30(2):233-244. PubMed ID: 28879833
[TBL] [Abstract][Full Text] [Related]
55. Estimating Progression Rates Across the Spectrum of Alzheimer's Disease for Amyloid-Positive Individuals Using National Alzheimer's Coordinating Center Data.
Potashman M; Buessing M; Levitchi Benea M; Cummings J; Borson S; Pemberton-Ross P; Epstein AJ
Neurol Ther; 2021 Dec; 10(2):941-953. PubMed ID: 34431074
[TBL] [Abstract][Full Text] [Related]
56. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MG; Tabet N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002854. PubMed ID: 28128435
[TBL] [Abstract][Full Text] [Related]
57. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
[TBL] [Abstract][Full Text] [Related]
58. Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT.
Clare L; Kudlicka A; Oyebode JR; Jones RW; Bayer A; Leroi I; Kopelman M; James IA; Culverwell A; Pool J; Brand A; Henderson C; Hoare Z; Knapp M; Morgan-Trimmer S; Burns A; Corbett A; Whitaker R; Woods B
Health Technol Assess; 2019 Mar; 23(10):1-242. PubMed ID: 30879470
[TBL] [Abstract][Full Text] [Related]
59. Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study.
Mazzeo S; Ingannato A; Giacomucci G; Manganelli A; Moschini V; Balestrini J; Cavaliere A; Morinelli C; Galdo G; Emiliani F; Piazzesi D; Crucitti C; Frigerio D; Polito C; Berti V; Bagnoli S; Padiglioni S; Sorbi S; Nacmias B; Bessi V
Eur J Neurol; 2024 Jan; 31(1):e16089. PubMed ID: 37797300
[TBL] [Abstract][Full Text] [Related]
60. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
Lamb HM; Goa KL
Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
